系统性红斑狼疮国际协作组(SLICC)起始队列中抗核抗体的纵向分析
该研究在805例新发系统性红斑狼疮(SLE)患者中,于入组时、第3年和第5年比较了两种HEp-2间接免疫荧光法(IFA1、IFA2)和一种ELISA法检测抗核抗体(ANA)的结果。三种方法阳性率均高且一致性较好,但5年随访中ELISA阳性率有所下降。作者认为,当考虑SLE诊断时,ELISA或HEp-2 IFA任一阴性可能需要反射检测。
要点
- 入组时至少一种ANA检测阳性者占99.6%,IFA1、IFA2和ELISA阳性率分别为96.1%、98.3%和96.6%。
- 第5年IFA1和IFA2阳性率仍高(95.2%、98.9%),ELISA阳性率降至91.3%(p<0.001)。
- 两种IFA在各时间点ANA阳性一致率>91%,荧光模式一致率≥71%。
核心结论
- 在新发SLE中,三种ANA检测方法表现出可互换性,阳性比例及滴度或吸光度单位均高。
- 5年随访期间ANA检测性能仅有轻度变异。
- 在考虑SLE诊断的临床情形下,ELISA或HEp-2 IFA任一检测阴性可能需要反射检测。
研究设计与样本
- 纵向分析国际新发SLE起始队列,患者定期复检并随访5年。
- 纳入805例SLE患者,采集入组时、第3年和第5年的人口学、临床和血清学数据。
- 在同一实验室进行两种HEp-2间接免疫荧光法(IFA1、IFA2)、一种ANA ELISA以及SLE相关自身抗体检测。
- 采用McNemar、Wilcoxon和kappa统计分别比较阳性频率、滴度或吸光度单位(AU)以及IFA荧光模式。
主要发现
- 入组时ANA阳性(≥1:80)率:IFA1为96.1%(中位滴度1:1280,IQR 1:640-1:5120),IFA2为98.3%(1:2560,IQR 1:640-1:5120),ELISA为96.6%(176.3 AU,IQR 106.4 AU-203.5 AU)。
- 入组时至少一种ANA检测阳性的患者占99.6%。
- 第5年IFA1阳性率为95.2%,IFA2为98.9%,ELISA阳性率降至91.3%(p<0.001)。
- IFA1与IFA2之间ANA阳性一致率在所有时间点均>91%,荧光模式一致率≥71%。
关键数值与推荐
- 入组时ANA阳性(≥1:80)率:IFA1 96.1%,IFA2 98.3%,ELISA 96.6%。
- 入组时中位滴度或吸光度单位:IFA1 1:1280(IQR 1:640-1:5120),IFA2 1:2560(IQR 1:640-1:5120),ELISA 176.3 AU(IQR 106.4 AU-203.5 AU)。
- 第5年ANA阳性率:IFA1 95.2%,IFA2 98.9%,ELISA 91.3%(p<0.001)。
- IFA1与IFA2之间ANA阳性一致率>91%,荧光模式一致率≥71%。
临床怎么用
- 原文结论指出,在考虑SLE诊断的临床情形下,ELISA或HEp-2 IFA任一检测阴性可能需要反射检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A perception derived from cross-sectional studies of small systemic lupus erythematosus (SLE) cohorts is that there is a marked discrepancy between antinuclear antibody (ANA) assays, which impacts on clinicians' approach to diagnosis and follow-up. We compared three ANA assays in a longitudinal analysis of a large international incident SLE cohort retested regularly and followed for 5 years. METHODS: Demographic, clinical and serological data was from 805 SLE patients at enrolment, year 3 and 5. Two HEp-2 indirect immunofluorescence assays (IFA1, IFA2), an ANA ELISA, and SLE-related autoantibodies were performed in one laboratory. Frequencies of positivity, titres or absorbance units (AU), and IFA patterns were compared using McNemar, Wilcoxon and kappa statistics, respectively. RESULTS: At enrolment, ANA positivity (≥1:80) was 96.1% by IFA1 (median titre 1:1280 (IQR 1:640-1:5120)), 98.3% by IFA2 (1:2560 (IQR 1:640-1:5120)) and 96.6% by ELISA (176.3 AU (IQR 106.4 AU-203.5 AU)). At least one ANA assay was positive for 99.6% of patients at enrolment. At year 5, ANA positivity by IFAs (IFA1 95.2%; IFA2 98.9%) remained high, while there was a decrease in ELISA positivity (91.3%, p<0.001). Overall, there was >91% agreement in ANA positivity at all time points and ≥71% agreement in IFA patterns between IFA1 and IFA2. CONCLUSION: In recent-onset SLE, three ANA assays demonstrated commutability with a high proportion of positivity and titres or AU. However, over 5 years follow-up, there was modest variation in ANA assay performance. In clinical situations where the SLE diagnosis is being considered, a negative test by either the ELISA or HEp-2 IFA may require reflex testing.
引用
- Choi MY, Clarke AE, Urowitz M, et al. Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2022. PMID: 35338033. doi:10.1136/annrheumdis-2022-222168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。